Specifically, they show that IRF-1 antagonizes IRF-2 for binding to the IRE promoter element in PD-L1, providing new insight into the regulation of PD1/PD-L1 pathways in HCC immune checkpoint blockade therapy [170]. This evidence concerns the gene IRF1 and hepatocellular carcinoma.